Fundamental index

RIGL Rigel Pharmaceuticals, Inc.

Healthcare · Biotechnology · US · as of 2026-07-17

B
Fundamental score
77.68

Reasons

  • Valuation 92: PE n/a, EV/EBITDA n/a, FCF yield 10.6%
  • Quality 90: ROE 147.0%, ROIC n/a, net margin 121.5%
  • Balance 78: debt/equity n/a, current ratio 2.62, Altman Z 3.33

Risk flags

No major cached red flags

Component scores

Quality90
Growth50
Balance78
Valuation92
Cash flow66

Key metrics

ROE
147.0% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
ROICn/a
Net margin
121.5% higher is usually better
-10%35%+
weak < 0%ok >= 10%strong >= 20%
Revenue growthn/a
Debt / equityn/a
Current ratio
2.62 above 1 is generally healthier
03+
risk < 1.0ok >= 1.0strong >= 2.0
Altman Z-score
3.33 higher usually means lower distress risk
04+
distress < 1.8grey 1.8-3.0safer > 3.0
PE ration/a
EV / EBITDAn/a
FCF yield
10.6% higher cash-flow yield is usually better
-5%15%+
weak < 0%ok >= 3%strong >= 8%

Revenue

294.28M 44.51M 44.51M 59.29M 108.62M 149.24M 120.24M 116.88M 179.28M 294.28M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: revenue values.

Net income

367.02M -70.48M -70.48M -66.55M -29.74M -17.91M -58.57M -25.09M 17.48M 367.02M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: net income values.

Free cash flow

75.66M -74.21M -59.93M -42.97M -53.45M 5.25M -74.21M -20.74M 31.07M 75.66M 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: free cash flow values.

Growth metrics

892.6% -19.4% 892.6% 33.2% 83.2% 37.4% -19.4% -2.8% 53.4% 64.1% 2018 2019 2020 2021 2022 2023 2024 2025

X-axis: fiscal years from cached FMP annual statement data. Y-axis: growth metrics values.

Abbreviations and definitions

ROE
ROE measures how much net profit a company generates from shareholders' equity.
ROIC
ROIC compares operating profit after tax with the capital invested in the business.
Net margin
Net margin shows how much net profit remains from revenue.
Revenue growth
Revenue growth measures how sales changed versus the comparable prior period.
Debt / equity
Debt to equity compares company debt with shareholders' equity.
Current ratio
Current ratio compares short-term assets with short-term liabilities.
Altman Z-score
Altman Z-score is a model estimating bankruptcy risk from financial ratios.
PE ratio
PE compares market price with earnings per share.
EV / EBITDA
EV/EBITDA compares total company value with operating earnings before depreciation and amortization.
FCF yield
FCF yield compares free cash flow with market value.
Revenue
Revenue is the total amount generated from selling goods or services before expenses.
Net income
Net income is profit after operating costs, interest, taxes and other expenses.
Free cash flow
Free cash flow is cash left after operating cash flow covers capital expenditures.
Growth metrics
Growth metrics summarize changes in revenue, profit or EPS versus a prior period.
EPS
EPS is net income allocated to each share.
EBITDA
EBITDA is earnings before interest, taxes, depreciation and amortization.
TTM
TTM is a rolling last-12-month view instead of one fiscal year.

This page is an automated factual summary of cached FMP data, not investment advice. Always verify source filings and liquidity before making decisions.